As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. Stock Symbol NASDAQ:SIRT ; Money Raised at IPO $60M; IPO Share Price $10.00; IPO Date May 23, 2007; Delisted Date Mar 13, 2013 GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Markets Data Center: Biggest Price Gainers. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. via: Sirtris Markets Data Center: Biggest Price Gainers. Sirtris Pharmaceuticals (NASDAQ:SIRT) ... as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in … Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. Latest Deal Amount. Find the latest Genocea Biosciences, Inc. (GNCA) stock quote, history, news and other vital information to help you with your stock trading and investing. © 2021 TheStreet, Inc. All rights reserved. As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. } Company profile page for Sirtris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated weekly. document.write("
Click here to add this page to your favorites"); GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated $376M. The news comes a day before Glaxo's quarterly earnings release. weekly.TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. The acquisition has been approved by the boards of both companies, and is expected to close in the second quarter. Sirtris PharmaceuticalsGeneral Information. When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. //-->. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … SIRTRIS PHARMA INC. Weekly Stock Prices Chart. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
